ABSTRACT
Regenerative medicine has the power to radically change the healthcare system from management and mitigation of serious illnesses to interventions that can cure at a single stroke. While the promise of the –eld is accordingly very high, it is perhaps only at the beginnings of its development, as measured by the number of commercial regenerative medicine approaches on the market today and the appetites of traditionally risk-tolerant investors such as venture capitalists and large pharmaceutical companies. In this chapter, we will seek to parse out the key elements of commercialization in the context of regenerative medicine with a speci–c focus on cell-based therapies and outline with case studies the roles tools and technology providers can play in expediting the commercialization process.
